Can the co-dependence of the immune system and angiogenesis facilitate pharmacological targeting of tumours?

Current Opinion in Pharmacology

Volumn 35, Issue , 2017, Pages 66-74

  Mortara, Lorenzo ^a   Benest, Andrew V ^b   Bates, David O ^b   Noonan, Douglas M ^a,c  

^a UNIVERSITY OF INSUBRIA   (Italy)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^c IRCCS MULTIMEDICA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANGIOGENIC THERAPY; BONE MARROW CELL; CANCER IMMUNOTHERAPY; DRUG TARGETING; GAMMA DELTA T LYMPHOCYTE; IMMUNE DEFICIENCY; IMMUNOREGULATION; INNATE IMMUNITY; LYMPHOID CELL; MOLECULARLY TARGETED THERAPY; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; TUMOR VASCULARIZATION; ANIMAL; HUMAN; IMMUNOLOGY; LYMPHOCYTE; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY;

ANIMALS; HUMANS; LYMPHOCYTES; MYELOID CELLS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 85020779791     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2017.05.009     Document Type: Review

References (95)

1. Noonan, D.M., De Lerma Barbaro, A., Vannini, N., Mortara, L., Albini, A., Inflammation, inflammatory cells and angiogenesis: decisions and indecisions. Cancer Metastasis Rev 27 (2008), 31–40.
2. Palucka, A.K., Coussens, L.M., The basis of oncoimmunology. Cell 164 (2016), 1233–1247.
3. Hanahan, D., Weinberg, R.A., Hallmarks of cancer: the next generation. Cell 144 (2011), 646–674.
4. Liang, W., Ferrara, N., The complex role of neutrophils in tumor angiogenesis and metastasis. Cancer Immunol Res 4 (2016), 83–91.
5. Sica, A., Erreni, M., Allavena, P., Porta, C., Macrophage polarization in pathology. Cell Mol Life Sci 72 (2015), 4111–4126.
6. Kitamura, T., Qian, B.Z., Pollard, J.W., Immune cell promotion of metastasis. Nat Rev Immunol 15 (2015), 73–86.
7. Ruffell, B., Coussens, L.M., Macrophages and therapeutic resistance in cancer. Cancer Cell 27 (2015), 462–472.
8. + PMN-MDSCs.
9. Lewis, C.E., Harney, A.S., Pollard, J.W., The multifaceted role of perivascular macrophages in tumors. Cancer Cell 30 (2016), 18–25.
10. Hughes, R., Qian, B.Z., Rowan, C., Muthana, M., Keklikoglou, I., Olson, O.C., Tazzyman, S., Danson, S., Addison, C., Clemons, M., et al. Perivascular M2 macrophages stimulate tumor relapse after chemotherapy. Cancer Res 75 (2015), 3479–3491.
11. 11• Teresa Pinto, A., Laranjeiro Pinto, M., Patricia Cardoso, A., Monteiro, C., Teixeira Pinto, M., Filipe Maia, A., Castro, P., Figueira, R., Monteiro, A., Marques, M., et al. Ionizing radiation modulates human macrophages towards a pro-inflammatory phenotype preserving their pro-invasive and pro-angiogenic capacities. Sci Rep, 6, 2016, 18765 This study supports the theory that ionizing radiation reduced anti-inflammatory phenotype of human monocyte-derived macrophages but was not able to restrain macrophage ability to trigger cancer cell invasion and cancer cell-induced angiogenesis.
12. Lin, L., Chen, Y.S., Yao, Y.D., Chen, J.Q., Chen, J.N., Huang, S.Y., Zeng, Y.J., Yao, H.R., Zeng, S.H., Fu, Y.S., et al. CCL18 from tumor-associated macrophages promotes angiogenesis in breast cancer. Oncotarget 6 (2015), 34758–34773.
13. 13•• Yeo, E.J., Cassetta, L., Qian, B.Z., Lewkowich, I., Li, J.F., Stefater, J.A. 3rd, Smith, A.N., Wiechmann, L.S., Wang, Y., Pollard, J.W., et al. Myeloid WNT7b mediates the angiogenic switch and metastasis in breast cancer. Cancer Res 74 (2014), 2962–2973 This study has revealed that the majority of human breast carcinomas showed up-regulation of ligand WNT7B using a mouse model of mammary carcinoma. The authors showed that tumour progression relied upon WNT7B production by myeloid cells in the microenvironment. Thus WNT7B as a key factor in the promotion of tumour progression, angiogenesis, invasion, and metastasis.
14. Vinnakota, K., Zhang, Y., Selvanesan, B.C., Topi, G., Salim, T., Sand-Dejmek, J., Jonsson, G., Sjolander, A., M2-like macrophages induce colon cancer cell invasion via matrix metalloproteinases. J Cell Physiol, 2017.
15. Deryugina, E.I., Quigley, J.P., Pleiotropic roles of matrix metalloproteinases in tumor angiogenesis: contrasting, overlapping and compensatory functions. Biochim Biophys Acta 1803 (2010), 103–120.
16. Kurahara, H., Takao, S., Maemura, K., Mataki, Y., Kuwahata, T., Maeda, K., Sakoda, M., Iino, S., Ishigami, S., Ueno, S., et al. M2-polarized tumor-associated macrophage infiltration of regional lymph nodes is associated with nodal lymphangiogenesis and occult nodal involvement in pN0 pancreatic cancer. Pancreas 42 (2013), 155–159.
17. Spiric, Z., Eri, Z., Eric, M., Significance of vascular endothelial growth factor (VEGF)-C and VEGF-D in the progression of cutaneous melanoma. Int J Surg Pathol 23 (2015), 629–637.
18. Ji, H., Cao, R., Yang, Y., Zhang, Y., Iwamoto, H., Lim, S., Nakamura, M., Andersson, P., Wang, J., Sun, Y., et al. TNFR1 mediates TNF-alpha-induced tumour lymphangiogenesis and metastasis by modulating VEGF-C-VEGFR3 signalling. Nat Commun, 5, 2014, 4944.
19. Yang, C., He, L., He, P., Liu, Y., Wang, W., He, Y., Du, Y., Gao, F., Increased drug resistance in breast cancer by tumor-associated macrophages through IL-10/STAT3/bcl-2 signaling pathway. Med Oncol, 32, 2015, 352.
20. Chung, F.T., Lee, K.Y., Wang, C.W., Heh, C.C., Chan, Y.F., Chen, H.W., Kuo, C.H., Feng, P.H., Lin, T.Y., Wang, C.H., et al. Tumor-associated macrophages correlate with response to epidermal growth factor receptor-tyrosine kinase inhibitors in advanced non-small cell lung cancer. Int J Cancer 131 (2012), E227–E235.
21. Gabrilovich, D.I., Myeloid-derived suppressor cells. Cancer Immunol Res 5 (2017), 3–8.
22. Bronte, V., Brandau, S., Chen, S.H., Colombo, M.P., Frey, A.B., Greten, T.F., Mandruzzato, S., Murray, P.J., Ochoa, A., Ostrand-Rosenberg, S., et al. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat Commun, 7, 2016, 12150.
23. Mandruzzato, S., Brandau, S., Britten, C.M., Bronte, V., Damuzzo, V., Gouttefangeas, C., Maurer, D., Ottensmeier, C., van der Burg, S.H., Welters, M.J., et al. Toward harmonized phenotyping of human myeloid-derived suppressor cells by flow cytometry: results from an interim study. Cancer Immunol Immunother 65 (2016), 161–169.
24. Condamine, T., Mastio, J., Gabrilovich, D.I., Transcriptional regulation of myeloid-derived suppressor cells. J Leukoc Biol 98 (2015), 913–922.
25. Messmer, M.N., Netherby, C.S., Banik, D., Abrams, S.I., Tumor-induced myeloid dysfunction and its implications for cancer immunotherapy. Cancer Immunol Immunother 64 (2015), 1–13.
26. Solito, S., Marigo, I., Pinton, L., Damuzzo, V., Mandruzzato, S., Bronte, V., Myeloid-derived suppressor cell heterogeneity in human cancers. Ann N Y Acad Sci 1319 (2014), 47–65.
27. Zhang, S., Ma, X., Zhu, C., Liu, L., Wang, G., Yuan, X., The role of myeloid-derived suppressor cells in patients with solid tumors: a meta-analysis. PLOS ONE, 11, 2016, e0164514.
28. Kumar, V., Patel, S., Tcyganov, E., Gabrilovich, D.I., The nature of myeloid-derived suppressor cells in the tumor microenvironment. Trends Immunol 37 (2016), 208–220.
29. Hoechst, B., Gamrekelashvili, J., Manns, M.P., Greten, T.F., Korangy, F., Plasticity of human Th17 cells and iTregs is orchestrated by different subsets of myeloid cells. Blood 117 (2011), 6532–6541.
30. Hoechst, B., Voigtlaender, T., Ormandy, L., Gamrekelashvili, J., Zhao, F., Wedemeyer, H., Lehner, F., Manns, M.P., Greten, T.F., Korangy, F., Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor. Hepatology 50 (2009), 799–807.
31. Kumar, V., Cheng, P., Condamine, T., Mony, S., Languino, L.R., McCaffrey, J.C., Hockstein, N., Guarino, M., Masters, G., Penman, E., et al. CD45 phosphatase inhibits STAT3 transcription factor activity in myeloid cells and promotes tumor-associated macrophage differentiation. Immunity 44 (2016), 303–315.
32. + cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 6 (2004), 409–421.
33. Shaul, M.E., Fridlender, Z.G., Neutrophils as active regulators of the immune system in the tumor microenvironment. J Leukoc Biol, 2017.
34. 34• Andzinski, L., Kasnitz, N., Stahnke, S., Wu, C.F., Gereke, M., von Kockritz-Blickwede, M., Schilling, B., Brandau, S., Weiss, S., Jablonska, J., Type I IFNs induce anti-tumor polarization of tumor associated neutrophils in mice and human. Int J Cancer 138 (2016), 1982–1993 In this manuscript the authors provide clear evidence that IFNβ has a major role in the polarization of neutrophils toward an anti-tumour phenotype in both mouse lung cancers and human melanomas.
35. Donskov, F., Immunomonitoring and prognostic relevance of neutrophils in clinical trials. Semin Cancer Biol 23 (2013), 200–207.
36. Cools-Lartigue, J., Spicer, J., McDonald, B., Gowing, S., Chow, S., Giannias, B., Bourdeau, F., Kubes, P., Ferri, L., Neutrophil extracellular traps sequester circulating tumor cells and promote metastasis. J Clin Invest, 2013.
37. Deryugina, E.I., Zajac, E., Juncker-Jensen, A., Kupriyanova, T.A., Welter, L., Quigley, J.P., Tissue-infiltrating neutrophils constitute the major in vivo source of angiogenesis-inducing MMP-9 in the tumor microenvironment. Neoplasia 16 (2014), 771–788.
38. Tecchio, C., Cassatella, M.A., Neutrophil-derived cytokines involved in physiological and pathological angiogenesis. Chem Immunol Allergy 99 (2014), 123–137.
39. 39•• Mishalian, I., Bayuh, R., Eruslanov, E., Michaeli, J., Levy, L., Zolotarov, L., Singhal, S., Albelda, S.M., Granot, Z., Fridlender, Z.G., Neutrophils recruit regulatory T-cells into tumors via secretion of CCL17 — a new mechanism of impaired antitumor immunity. Int J Cancer 135 (2014), 1178–1186 This study shows that TANs are able to recruit Treg cells via CCL17 release both in mice and human, illustrating a new indirect mechanism by which TANs may inhibit antitumor immune activity.
40. Dumitru, C.A., Lang, S., Brandau, S., Modulation of neutrophil granulocytes in the tumor microenvironment: mechanisms and consequences for tumor progression. Semin Cancer Biol 23 (2013), 141–148.
41. Sudam Patil, R., Umesh Shah, S., Vinayak Shrikhande, S., Goel, M., Prabhakar Dikshit, R., Vivek Chiplunkar, S., IL17 producing gammadeltaT cells induce angiogenesis and are associated with poor survival in gallbladder cancer patients. Int J Cancer 139 (2016), 869–881.
42. Terme, M., Pernot, S., Marcheteau, E., Sandoval, F., Benhamouda, N., Colussi, O., Dubreuil, O., Carpentier, A.F., Tartour, E., Taieb, J., VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer. Cancer Res 73 (2013), 539–549.
43. Donini, M., Buti, S., Lazzarelli, S., Bozzetti, R., Rivoltini, L., Camisaschi, C., Castelli, C., Bearz, A., Simonelli, C., Lo Re, G., et al. Dose-finding/phase II trial: bevacizumab, immunotherapy, and chemotherapy (BIC) in metastatic renal cell cancer (mRCC). Antitumor effects and variations of circulating T regulatory cells (Treg). Target Oncol 10 (2015), 277–286.
44. Carrega, P., Campana, S., Bonaccorsi, I., Ferlazzo, G., The Yin and Yang of innate lymphoid cells in cancer. Immunol Lett 179 (2016), 29–35.
45. Montaldo, E., Vacca, P., Vitale, C., Moretta, F., Locatelli, F., Mingari, M.C., Moretta, L., Human innate lymphoid cells. Immunol Lett 179 (2016), 2–8.
46. Vallentin, B., Barlogis, V., Piperoglou, C., Cypowyj, S., Zucchini, N., Chene, M., Navarro, F., Farnarier, C., Vivier, E., Vely, F., Innate lymphoid cells in cancer. Cancer Immunol Res 3 (2015), 1109–1114.
47. Bruno, A., Ferlazzo, G., Albini, A., Noonan, D.M., A think tank of TINK/TANKs: tumor-infiltrating/tumor-associated natural killer cells in tumor progression and angiogenesis. J Natl Cancer Inst, 106, 2014.
48. Bruno, A., Pagani, A., Pulze, L., Albini, A., Dallaglio, K., Noonan, D.M., Mortara, L., Orchestration of angiogenesis by immune cells. Front Oncol, 4, 2014, 131.
49. Remark, R., Alifano, M., Cremer, I., Lupo, A., Dieu-Nosjean, M.C., Riquet, M., Crozet, L., Ouakrim, H., Goc, J., Cazes, A., et al. Characteristics and clinical impacts of the immune environments in colorectal and renal cell carcinoma lung metastases: influence of tumor origin. Clin Cancer Res 19 (2013), 4079–4091.
50. Bruno, A., Focaccetti, C., Pagani, A., Imperatori, A.S., Spagnoletti, M., Rotolo, N., Cantelmo, A.R., Franzi, F., Capella, C., Ferlazzo, G., et al. The proangiogenic phenotype of natural killer cells in patients with non-small cell lung cancer. Neoplasia 15 (2013), 133–142.
51. Morandi, F., Horenstein, A.L., Chillemi, A., Quarona, V., Chiesa, S., Imperatori, A., Zanellato, S., Mortara, L., Gattorno, M., Pistoia, V., et al. CD56brightCD16− NK cells produce adenosine through a CD38-mediated pathway and act as regulatory cells inhibiting autologous CD4+ T cell proliferation. J Immunol 195 (2015), 965–972.
52. Mattner, J., Wirtz, S., Friend or foe? The ambiguous role of innate lymphoid cells in cancer development. Trends Immunol 38 (2017), 29–38.
53. 53•• Monticelli, L.A., Osborne, L.C., Noti, M., Tran, S.V., Zaiss, D.M., Artis, D., IL-33 promotes an innate immune pathway of intestinal tissue protection dependent on amphiregulin–EGFR interactions. Proc Natl Acad Sci U S A 112 (2015), 10762–10767 Using a murine model of intestinal damage and inflammation, this study demonstrates that IL-33 activated ILC2s are effective in the restoration of epithelial barrier function and maintenance of tissue homeostasis via amphiregulin/EGFR interactions.
54. Zaiss, D.M., van Loosdregt, J., Gorlani, A., Bekker, C.P., Grone, A., Sibilia, M., van Bergen en Henegouwen, P.M., Roovers, R.C., Coffer, P.J., Sijts, A.J., Amphiregulin enhances regulatory T cell-suppressive function via the epidermal growth factor receptor. Immunity 38 (2013), 275–284.
55. Geremia, A., Arancibia-Carcamo, C.V., Fleming, M.P., Rust, N., Singh, B., Mortensen, N.J., Travis, S.P., Powrie, F., IL-23-responsive innate lymphoid cells are increased in inflammatory bowel disease. J Exp Med 208 (2011), 1127–1133.
56. Kirchberger, S., Royston, D.J., Boulard, O., Thornton, E., Franchini, F., Szabady, R.L., Harrison, O., Powrie, F., Innate lymphoid cells sustain colon cancer through production of interleukin-22 in a mouse model. J Exp Med 210 (2013), 917–931.
57. 57•• Pan, B., Shen, J., Cao, J., Zhou, Y., Shang, L., Jin, S., Cao, S., Che, D., Liu, F., Yu, Y., Interleukin-17 promotes angiogenesis by stimulating VEGF production of cancer cells via the STAT3/GIV signaling pathway in non-small-cell lung cancer. Sci Rep, 5, 2015, 16053 This study demonstrates a key role for IL-17 in the promotion of vessel-like tubes in a dose-dependent manner and that in NSCLC intra-tumour IL-17-producing cells promote angiogenesis via STAT3/GIV activation.
58. Gabrilovich, D., Ishida, T., Oyama, T., Ran, S., Kravtsov, V., Nadaf, S., Carbone, D.P., Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 92 (1998), 4150–4166.
59. Gabrilovich, D.I., Ishida, T., Nadaf, S., Ohm, J.E., Carbone, D.P., Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin Cancer Res 5 (1999), 2963–2970.
60. Dirkx, A.E., Oude Egbrink, M.G., Kuijpers, M.J., van der Niet, S.T., Heijnen, V.V., Bouma-ter Steege, J.C., Wagstaff, J., Griffioen, A.W., Tumor angiogenesis modulates leukocyte-vessel wall interactions in vivo by reducing endothelial adhesion molecule expression. Cancer Res 63 (2003), 2322–2329.
61. Gordon, E.J., Fukuhara, D., Westrom, S., Padhan, N., Sjostrom, E.O., van Meeteren, L., He, L., Orsenigo, F., Dejana, E., Bentley, K., et al. The endothelial adaptor molecule TSAd is required for VEGF-induced angiogenic sprouting through junctional c-Src activation. Sci Signal, 9, 2016, ra72.
62. Schonle, A., Hartl, F.A., Mentzel, J., Noltner, T., Rauch, K.S., Prestipino, A., Wohlfeil, S.A., Apostolova, P., Hechinger, A.K., Melchinger, W., et al. Caveolin-1 regulates TCR signal strength and regulatory T-cell differentiation into alloreactive T cells. Blood 127 (2016), 1930–1939.
63. Hodi, F.S., Lawrence, D., Lezcano, C., Wu, X., Zhou, J., Sasada, T., Zeng, W., Giobbie-Hurder, A., Atkins, M.B., Ibrahim, N., et al. Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer Immunol Res 2 (2014), 632–642.
64. Huang, H., Langenkamp, E., Georganaki, M., Loskog, A., Fuchs, P.F., Dieterich, L.C., Kreuger, J., Dimberg, A., VEGF suppresses T-lymphocyte infiltration in the tumor microenvironment through inhibition of NF-kappaB-induced endothelial activation. FASEB J 29 (2015), 227–238.
65. 65•• Wu, X., Giobbie-Hurder, A., Liao, X., Lawrence, D., McDermott, D., Zhou, J., Rodig, S., Hodi, F.S., VEGF neutralization plus CTLA-4 blockade alters soluble and cellular factors associated with enhancing lymphocyte infiltration and humoral recognition in melanoma. Cancer Immunol Res 4 (2016), 858–868 In this article results from phase I clinical trial of ipilimumab in combination with bevacizumab in patients with metastatic melanoma showed favorable clinical outcomes that correlated with increased tumor endothelial expression of ICAM1 and VCAM1, up-regulation of plasma IL1α, TNFα and CXCL10, enhanced T cell adhesion and increased anti-tumor humoral immune responses.
66. Wu, X., Li, J., Connolly, E.M., Liao, X., Ouyang, J., Giobbie-Hurder, A., Lawrence, D., McDermott, D., Murphy, G., Zhou, J., et al. Combined anti-VEGF and anti-CTLA-4 therapy elicits humoral immunity to galectin-1 which is associated with favorable clinical outcomes. Cancer Immunol Res 5 (2017), 446–454.
67. Allen, E., Jabouille, A., Rivera, L.B., Lodewijckx, I., Missiaen, R., Steri, V., Feyen, K., Tawney, J., Hanahan, D., Michael, I.P., et al. Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation. Sci Transl Med, 9, 2017.
68. 68• Schmittnaegel, M., Rigamonti, N., Kadioglu, E., Cassara, A., Wyser Rmili, C., Kiialainen, A., Kienast, Y., Mueller, H.J., Ooi, C.H., Laoui, D., et al. Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade. Sci Transl Med, 9, 2017 This study demonstrated that the combination of anti-VEGFR2, anti-Ang2 and anti-PD-L1 antibody treatment cooperate in murine pancreatic and mammary tumors in enhancing HEV formation, favoring CTL infiltration and subsequent tumor cell killing.
69. Pyonteck, S.M., Akkari, L., Schuhmacher, A.J., Bowman, R.L., Sevenich, L., Quail, D.F., Olson, O.C., Quick, M.L., Huse, J.T., Teijeiro, V., et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med 19 (2013), 1264–1272.
70. Ries, C.H., Cannarile, M.A., Hoves, S., Benz, J., Wartha, K., Runza, V., Rey-Giraud, F., Pradel, L.P., Feuerhake, F., Klaman, I., et al. Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell 25 (2014), 846–859.
71. Albini, A., Brigati, C., Ventura, A., Lorusso, G., Pinter, M., Morini, M., Mancino, A., Sica, A., Noonan, D.M., Angiostatin anti-angiogenesis requires IL-12: the innate immune system as a key target. J Transl Med, 7, 2009, 5.
72. Acquati, F., Bertilaccio, S., Grimaldi, A., Monti, L., Cinquetti, R., Bonetti, P., Lualdi, M., Vidalino, L., Fabbri, M., Sacco, M.G., et al. Microenvironmental control of malignancy exerted by RNASET2, a widely conserved extracellular RNase. Proc Natl Acad Sci U S A 108 (2011), 1104–1109.
73. Baer, C., Squadrito, M.L., Laoui, D., Thompson, D., Hansen, S.K., Kiialainen, A., Hoves, S., Ries, C.H., Ooi, C.H., De Palma, M., Suppression of microRNA activity amplifies IFN-gamma-induced macrophage activation and promotes anti-tumour immunity. Nat Cell Biol 18 (2016), 790–802.
74. Brahmi, M., Vinceneux, A., Cassier, P.A., Current systemic treatment options for tenosynovial giant cell tumor/pigmented villonodular synovitis: targeting the CSF1/CSF1R axis. Curr Treat Options Oncol, 17, 2016, 10.
75. Butowski, N., Colman, H., De Groot, J.F., Omuro, A.M., Nayak, L., Wen, P.Y., Cloughesy, T.F., Marimuthu, A., Haidar, S., Perry, A., et al. Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study. Neuro Oncol 18 (2016), 557–564.
76. Brana, I., Calles, A., LoRusso, P.M., Yee, L.K., Puchalski, T.A., Seetharam, S., Zhong, B., de Boer, C.J., Tabernero, J., Calvo, E., Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study. Target Oncol 10 (2015), 111–123.
77. Pienta, K.J., Machiels, J.P., Schrijvers, D., Alekseev, B., Shkolnik, M., Crabb, S.J., Li, S., Seetharam, S., Puchalski, T.A., Takimoto, C., et al. Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer. Invest New Drugs 31 (2013), 760–768.
78. Sandhu, S.K., Papadopoulos, K., Fong, P.C., Patnaik, A., Messiou, C., Olmos, D., Wang, G., Tromp, B.J., Puchalski, T.A., Balkwill, F., et al. A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors. Cancer Chemother Pharmacol 71 (2013), 1041–1050.
79. Papadopoulos, K.P., Kelley, R.K., Tolcher, A.W., Razak, A.R., Van Loon, K., Patnaik, A., Bedard, P.L., Alfaro, A.A., Beeram, M., Adriaens, L., et al. A phase I first-in-human study of nesvacumab (REGN910), a fully human anti-angiopoietin-2 (Ang2) monoclonal antibody, in patients with advanced solid tumors. Clin Cancer Res 22 (2016), 1348–1355.
80. Allavena, P., Germano, G., Belgiovine, C., D'Incalci, M., Mantovani, A., Trabectedin: a drug from the sea that strikes tumor-associated macrophages. Oncoimmunology, 2, 2013, e24614.
81. Germano, G., Frapolli, R., Belgiovine, C., Anselmo, A., Pesce, S., Liguori, M., Erba, E., Uboldi, S., Zucchetti, M., Pasqualini, F., et al. Role of macrophage targeting in the antitumor activity of trabectedin. Cancer Cell 23 (2013), 249–262.
82. Dossi, R., Frapolli, R., Di Giandomenico, S., Paracchini, L., Bozzi, F., Brich, S., Castiglioni, V., Borsotti, P., Belotti, D., Uboldi, S., et al. Antiangiogenic activity of trabectedin in myxoid liposarcoma: involvement of host TIMP-1 and TIMP-2 and tumor thrombospondin-1. Int J Cancer 136 (2015), 721–729.
83. Ramachandran, I.R., Condamine, T., Lin, C., Herlihy, S.E., Garfall, A., Vogl, D.T., Gabrilovich, D.I., Nefedova, Y., Bone marrow PMN-MDSCs and neutrophils are functionally similar in protection of multiple myeloma from chemotherapy. Cancer Lett 371 (2016), 117–124.
84. Vetsika, E.K., Koinis, F., Gioulbasani, M., Aggouraki, D., Koutoulaki, A., Skalidaki, E., Mavroudis, D., Georgoulias, V., Kotsakis, A., A circulating subpopulation of monocytic myeloid-derived suppressor cells as an independent prognostic/predictive factor in untreated non-small lung cancer patients. J Immunol Res, 2014, 2014, 659294.
85. Meyer, C., Cagnon, L., Costa-Nunes, C.M., Baumgaertner, P., Montandon, N., Leyvraz, L., Michielin, O., Romano, E., Speiser, D.E., Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab. Cancer Immunol Immunother 63 (2014), 247–257.
86. Tarhini, A.A., Edington, H., Butterfield, L.H., Lin, Y., Shuai, Y., Tawbi, H., Sander, C., Yin, Y., Holtzman, M., Johnson, J., et al. Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab. PLOS ONE, 9, 2014, e87705.
87. Highfill, S.L., Cui, Y., Giles, A.J., Smith, J.P., Zhang, H., Morse, E., Kaplan, R.N., Mackall, C.L., Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy. Sci Transl Med, 6, 2014, 237ra267.
88. Weber, J., Gibney, G., Kudchadkar, R., Yu, B., Cheng, P., Martinez, A.J., Kroeger, J., Richards, A., McCormick, L., Moberg, V., et al. Phase I/II study of metastatic melanoma patients treated with nivolumab who had progressed after ipilimumab. Cancer Immunol Res 4 (2016), 345–353.
89. Iclozan, C., Antonia, S., Chiappori, A., Chen, D.T., Gabrilovich, D., Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer. Cancer Immunol Immunother 62 (2013), 909–918.
90. Condamine, T., Kumar, V., Ramachandran, I.R., Youn, J.I., Celis, E., Finnberg, N., El-Deiry, W.S., Winograd, R., Vonderheide, R.H., English, N.R., et al. ER stress regulates myeloid-derived suppressor cell fate through TRAIL-R-mediated apoptosis. J Clin Invest 124 (2014), 2626–2639.
91. Galluzzi, L., Zitvogel, L., Kroemer, G., Immunological mechanisms underneath the efficacy of cancer therapy. Cancer Immunol Res 4 (2016), 895–902.
92. He, S., Yin, T., Li, D., Gao, X., Wan, Y., Ma, X., Ye, T., Guo, F., Sun, J., Lin, Z., et al. Enhanced interaction between natural killer cells and lung cancer cells: involvement in gefitinib-mediated immunoregulation. J Transl Med, 11, 2013, 186.
93. Xu, Y., Sun, J., Sheard, M.A., Tran, H.C., Wan, Z., Liu, W.Y., Asgharzadeh, S., Sposto, R., Wu, H.W., Seeger, R.C., Lenalidomide overcomes suppression of human natural killer cell anti-tumor functions by neuroblastoma microenvironment-associated IL-6 and TGFbeta1. Cancer Immunol Immunother 62 (2013), 1637–1648.
94. Albini, A., Tosetti, F., Li, V.W., Noonan, D.M., Li, W.W., Cancer prevention by targeting angiogenesis. Nat Rev Clin Oncol 9 (2012), 498–509.
95. Derlindati, E., Dall'Asta, M., Ardigo, D., Brighenti, F., Zavaroni, I., Crozier, A., Del Rio, D., Quercetin-3-O-glucuronide affects the gene expression profile of M1 and M2a human macrophages exhibiting anti-inflammatory effects. Food Funct 3 (2012), 1144–1152.